According to Rush et al, treatment resistance falls on a continuum.8 Modest, resistance may include an inadequate response to a single antidepressant trial, whereas greater resistance selleckchem refers to failure of two monotherapy trials or one or more augmentation trials. Various staging schemes have been proposed for TRD, taking into
consideration greater or lesser resistance according to the number of adequately delivered trials (in terms of dose, duration, and adherence) given to patients with properly diagnosed disease.9,10 Souery et al proposed an operational definition for TRD as the failure to respond to two adequate trials of different, classes of antidepressants.11 Similarly, Sackeim Inhibitors,research,lifescience,medical et al proposed that clinically significant, treatment resistance is present if depression has not benefited from at least, two adequate trials Inhibitors,research,lifescience,medical of medications
from different classes in the current episode.12 Traditionally, treatment resistance has focused on nonresponsc (eg, minimal or no improvement on drug therapy). From the perspective of clinicians and patients, not achieving full remission represents a significant burden and therefore full remission should be the optimal goal.13 Partial response refers to the situation Inhibitors,research,lifescience,medical wherein an individual has responded to antidepressant treatment but still has significant residual symptoms that interfere with work, family, and social activities. Remission as the goal of treatment The chronic nature of MDD contributes to difficulty in achieving the goal of remission Inhibitors,research,lifescience,medical – ie, full return to premorbid functioning between episodes. Residual symptoms of depression (including low mood, early insomnia, weight loss, and hopelessness) are often accompanied by significant occupational and psychosocial dysfunction, as well as being associated with early relapse and increased recurrence rates.14,15
There is considerable evidence that even with treatment, residual symptoms often persist, leading Inhibitors,research,lifescience,medical to psychosocial dysfunction,16-18 and the longer a patient remains symptomatic, the lower the chances of a complete AV-951 recovery.17 Treatment strategies to achieve remission Pharmacological treatments Initial treatment – monotherapy versus combination therapy Evidence to date suggests that the longer it takes to get to remission (ie, the more treatment trials required), the greater the risk of treatment resistance. Consensus opinion therefore suggests that aggressive initial treatment, is the most, appropriate strategy. Medications recommended for initial treatment of a major depressive episode (MD.E) include selective full report serotonin reuptake inhibitors (SSRIs – fluoxetine, paroxetine, sertraline, citalopram, and escitalopram), serotonergic noradrenergic reuptake inhibitors (SNRIs – venlafaxine and duloxetine), bupropion, and mirtazapinc.